[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69531476D1 - Serotonergische Modulatoren - Google Patents

Serotonergische Modulatoren

Info

Publication number
DE69531476D1
DE69531476D1 DE69531476T DE69531476T DE69531476D1 DE 69531476 D1 DE69531476 D1 DE 69531476D1 DE 69531476 T DE69531476 T DE 69531476T DE 69531476 T DE69531476 T DE 69531476T DE 69531476 D1 DE69531476 D1 DE 69531476D1
Authority
DE
Germany
Prior art keywords
optionally substituted
alkyl
hydrogen
substituted phenyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69531476T
Other languages
English (en)
Other versions
DE69531476T2 (de
Inventor
Jeremy Gilmore
Peter Thaddeus Gallagher
Martin Victor Miles
William Martin Owton
Colin William Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilly Industries Ltd
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9418326A external-priority patent/GB9418326D0/en
Priority claimed from GBGB9511166.2A external-priority patent/GB9511166D0/en
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Application granted granted Critical
Publication of DE69531476D1 publication Critical patent/DE69531476D1/de
Publication of DE69531476T2 publication Critical patent/DE69531476T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Optical Integrated Circuits (AREA)
  • Holo Graphy (AREA)
  • Gyroscopes (AREA)
DE69531476T 1994-09-12 1995-09-07 Serotonergische Modulatoren Expired - Fee Related DE69531476T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9418326 1994-09-12
GB9418326A GB9418326D0 (en) 1994-09-12 1994-09-12 Pharmaceutical compounds
GB9511166 1995-06-02
GBGB9511166.2A GB9511166D0 (en) 1995-06-02 1995-06-02 Pharmaceutical compounds

Publications (2)

Publication Number Publication Date
DE69531476D1 true DE69531476D1 (de) 2003-09-18
DE69531476T2 DE69531476T2 (de) 2004-06-09

Family

ID=26305611

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69531476T Expired - Fee Related DE69531476T2 (de) 1994-09-12 1995-09-07 Serotonergische Modulatoren

Country Status (22)

Country Link
EP (1) EP0705832B1 (de)
JP (1) JPH0881464A (de)
KR (1) KR960010635A (de)
CN (1) CN1045602C (de)
AT (1) ATE247114T1 (de)
AU (1) AU698580B2 (de)
CA (1) CA2157998A1 (de)
CZ (1) CZ286565B6 (de)
DE (1) DE69531476T2 (de)
ES (1) ES2204932T3 (de)
FI (1) FI954243A (de)
HU (1) HU219491B (de)
IL (1) IL115236A (de)
IN (1) IN179550B (de)
MY (1) MY132009A (de)
NO (1) NO305174B1 (de)
NZ (1) NZ272961A (de)
PE (1) PE41796A1 (de)
PH (1) PH31631A (de)
PL (1) PL310373A1 (de)
RU (1) RU2146256C1 (de)
TR (1) TR199501114A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
EP0905136A1 (de) * 1997-09-08 1999-03-31 Janssen Pharmaceutica N.V. Tetrahydro gamma-Carboline
UA70334C2 (en) * 1998-10-06 2004-10-15 Janssen Pharmaceutica N V Jans BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
WO2002004409A2 (en) * 2000-07-06 2002-01-17 Us Gov Health & Human Serv Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10040016A1 (de) * 2000-08-16 2002-02-28 Boehringer Ingelheim Pharma Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
MXPA03002329A (es) * 2000-09-19 2003-10-15 Boehringer Ingelheim Pharma Nuevos derivados de bencimidazolona que muestran afinidad por los receptores de serotonina y dopamina.
CA2417081C (en) * 2000-09-19 2008-08-05 Enzo Cereda New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
ES2250689T3 (es) 2001-08-08 2006-04-16 PHARMACIA & UPJOHN COMPANY LLC 1h-pirido(4,3-b)indoles terapeuticos.
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
WO2007014929A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
JP2009513604A (ja) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
AU2007287639A1 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
MX2011012537A (es) * 2009-05-29 2011-12-14 Sumitomo Chemical Co Agente para el tratamiento o prevencion de enfermedades asociadas con actividad de factores neurotroficos.
US10292971B2 (en) * 2015-10-01 2019-05-21 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4035369A (en) 1975-10-08 1977-07-12 Janssen Pharmaceutica N.V. 1-Benzazolylalkyl-4-substituted-piperidines
IL69132A (en) * 1982-07-14 1986-02-28 Roussel Uclaf Benzo-and naphtho-thiopyranopyrimidinones,their preparation and pharmaceutical compositions containing them
FR2661177A1 (fr) * 1990-04-23 1991-10-25 Rhone Poulenc Sante Derives du naphtosultame antagonistes de la serotonine, leur preparation et les medicaments les contenant.

Also Published As

Publication number Publication date
HU219491B (hu) 2001-04-28
PL310373A1 (en) 1996-03-18
NO305174B1 (no) 1999-04-12
ES2204932T3 (es) 2004-05-01
CZ232295A3 (en) 1996-03-13
NZ272961A (en) 1998-02-26
IN179550B (de) 1997-10-18
IL115236A0 (en) 1995-12-31
AU698580B2 (en) 1998-11-05
FI954243A0 (fi) 1995-09-11
JPH0881464A (ja) 1996-03-26
NO953575L (no) 1996-03-13
EP0705832A1 (de) 1996-04-10
CN1129219A (zh) 1996-08-21
CA2157998A1 (en) 1996-03-13
RU2146256C1 (ru) 2000-03-10
KR960010635A (ko) 1996-04-20
MY132009A (en) 2007-09-28
FI954243A (fi) 1996-03-13
HU9502631D0 (en) 1995-11-28
AU3049795A (en) 1996-03-28
CZ286565B6 (cs) 2000-05-17
DE69531476T2 (de) 2004-06-09
CN1045602C (zh) 1999-10-13
PE41796A1 (es) 1996-10-21
TR199501114A2 (tr) 1996-10-21
IL115236A (en) 1998-06-15
PH31631A (en) 1999-01-12
ATE247114T1 (de) 2003-08-15
HUT72593A (en) 1996-05-28
EP0705832B1 (de) 2003-08-13
NO953575D0 (no) 1995-09-11

Similar Documents

Publication Publication Date Title
ATE247114T1 (de) Serotonergische modulatoren
AU537414B2 (en) Pyroglutamic acid derivatives
DE69634733D1 (de) Benzamidoxime prodrugs und verwendung zur behandlung von pneumonie
DE19680619D2 (de) Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
NO934718D0 (no) Nye HIV protease inhibitorer
AU3113793A (en) Intermediates for preparing antipicornaviral pyridazinamines
DE69707372D1 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
DE59607208D1 (de) Verwendung eines Natrium- oder Lysiniumsalzes von Crotonsäureamidderivaten zur Herstellung eines Arzneimittels zur Behandlung von Krebserkrankungen
FI914007A0 (fi) 4-substituerade dihydropyrido (4,3-d) pyrimidiner som smaertslindrande och lokala inflammationshaemmande medel vid vaord av hudsjukdomar.
DE3567647D1 (en) N-(azolylcarbamoyl)-hydroxyl amines and fungicides containing them
DK0387489T3 (da) Anvendelse af 2,2,6,6-tetramethyl-4-aminopiperidinamider som fungicider
NZ316516A (en) quinoline substituted carbamoyl carboxylic acid amides and medicaments
NO304314B1 (no) Cykloheksanderivater og anvendelse av forbindelsene for fremstilling av legemidler
NO972943D0 (no) 4-amino-2-ureido-pyrimidin-5-karboksylsyreamider, fremgangsmåter for deres fremstilling, legemidler inneholdende disse forbindelsene og deres anvendelse
ATE31059T1 (de) N-(arylpropyl)-azolylharnstoffe und diese enthaltende fungizide.
ATE192141T1 (de) Aromatische hydroxamsäure-verbindungen, ihre herstellung und verwendung
DK347387D0 (da) Amidderivater
DE60005525D1 (de) 2-aminotetraline zur behandlung von glaukom
DE69327077D1 (de) Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen
NO972942D0 (no) 4-amino-2-ureido-pyrimidin-5-karboksylsyreamider, fremgangsmåter for deres fremstilling, legemidler inneholdende disse forbindelsene og deres anvendelse
ECSP951529A (es) Compuestos farmaceuticos

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee